There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Inari Medical Inc. (NARI) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $59.12. The Inari Medical Inc. has recorded 20,871 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
This NASDAQ-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $59.12 and fluctuated between $59.58 as its day high and $55.78 as its day low. The current market capitalization of Inari Medical Inc. is $3.28B. A total of 0.77 million shares were traded on the day, compared to an average of 819.86K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NARI has seen 8 BUY and 62 SELL insider trades, representing the acquisition of 335,873 and the disposition of 224,250 shares. Over the last 12 months, there were 37 BUYs and 250 SELLs from insiders. Insiders purchased 643,182 shares during that period but sold 1,375,381.
In the most recent transaction, Tu Thomas sold 10,000 shares of NARI for 56.72 per share on Feb 27. After the transaction, the Chief Medical Officer now owns 107,112 company shares. In a previous transaction on Feb 21, Hykes Andrew sold 9,000 shares at 55.19 per share. NARI shares that President and CEO owns now total 130,595.
Among the insiders who sold shares, Hoffman William disposed of 50,000 shares on Feb 15 at a per-share price of $58.59. This resulted in the Director holding 296,190 shares of NARI after the transaction. In another insider transaction, Hill, Mitch C. sold 12,750 shares at $53.82 per share on Feb 13. Company shares held by the Chief Financial Officer now total 46,480.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NARI in the last 3 months, the mean price target is $91.13 with high estimates of $105.00 and low estimates of $65.00. In terms of 52-week highs and lows, NARI has a high of $95.39 and a low of $50.50.
As of this writing, NARI has an earnings estimate of -$0.17 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.16 per share and a lower estimate of -$0.18. The company reported an EPS of -$0.19 in the last quarter, which was 17.40% higher than expectations of -$0.23.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NARI is Overweight with a score of 4.63. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.